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Abstract
The standard proteinogenic amino acids grant access to a myriad of chemistries that harmonize to 
create life. Outside of these twenty canonical protein building blocks are countless noncanonical 
amino acids (ncAAs), either found in nature or created by man. Interest in ncAAs has grown as 
research has unveiled their importance as precursors to natural products and pharmaceuticals, 
biological probes, and more. Despite their broad applications, synthesis of ncAAs remains a 
challenge, as poor stereoselectivity and low functional-group compatibility stymie effective 
preparative routes. The use of enzymes has emerged as a versatile approach to prepare ncAAs, and 
nature’s enzymes can be engineered to synthesize ncAAs more efficiently and expand the amino 
acid alphabet. In this tutorial review, we briefly outline different enzyme engineering strategies 
and then discuss examples where engineering has generated new ‘ncAA synthases’ for efficient, 
environmentally benign production of a wide and growing collection of valuable ncAAs.
Key Learning Points:
• Important applications of ncAAs in medicine, chemistry, and biology
• Advantages and disadvantages of current approaches for synthesizing ncAAs
• Strategies for enzyme engineering
• Cases where ncAA synthases have been created or optimized with enzyme 
engineering
• Opportunities for further exploration and progress in biocatalytic ncAA synthesis
1. Introduction
The twenty canonical L-α-amino acids (Scheme 1a) that serve as the primary basis of protein 
structure and function comprise only a small fraction of biologically and technologically 
important amino acids. Noncanonical amino acids (ncAAs), which are not naturally 
incorporated into proteins during translation, contain unusual side chains, D stereochemistry, 
or atypical backbone connectivity (Scheme 1b). These features in turn impart distinct 
chemical and biological properties, such as greater stability in vivo. These properties have 
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elicited considerable interest, and ncAAs are used as therapeutics1 and synthetic 
intermediates,2 and are even encoded directly into proteins to confer useful new features.3
Noncanonical amino acids are challenging to synthesize because they often contain a 
stereocenter at the α-carbon, which must be set in a precise configuration. In addition, the 
amine and carboxylic acid groups are reactive and often have to be protected. These 
problems are compounded when ncAAs have complex side chains that contain additional 
stereocenters or reactive functional groups. Nature circumvents such challenges by using 
enzymes, which bind and position substrates to accelerate a specific reaction, making 
enantiopure amino acids in aqueous media without the need for protecting groups. However, 
many enzymes that produce ncAAs in nature are not suitable for preparative ncAA synthesis 
due to low activity, poor endogenous expression and stability, need for allosteric activation, 
or limited substrate scope. Furthermore, many ncAAs are naturally synthesized via 
complicated multi-enzyme cascades, which may be difficult to identify and use for synthesis 
at scale. New strategies are needed for ncAA synthesis, and engineering new or improved 
enzymes offers some promising leads.
A number of enzymes have activities that could be used to make ncAAs, and protein 
engineering has been an indispensable tool for expanding this latent potential. Researchers 
have been able to requisition existing enzymes and engineer them to create high-yielding 
biocatalytic platforms that generate enantiomerically pure ncAAs. We will refer to these 
enzymes as ‘ncAA synthases’, since they are used to couple two molecules without 
requiring additional energetic input (e.g., ATP). Well-designed mutagenesis and screening 
strategies facilitate the engineering process, and iterative rounds of mutagenesis and 
screening (directed evolution) can produce greatly improved ncAA synthases; expanded 
substrate scopes, enhanced stability and heterologous expression, and increased yields are all 
achievable with the appropriate experimental design. In this tutorial review, we will illustrate 
principles of protein engineering and evolution in the context of ncAA synthases. To focus 
the scope of this review, we will primarily explore the synthesis and applications of α-amino 
acids, and direct the readers interested in different configurations to other excellent works4,5. 
We will begin by introducing the importance of ncAAs in chemistry and medicine and 
comparing current methods for producing ncAAs. We will then cover principles of protein 
engineering and evolution before exploring cases where researchers have applied these 
principles to address fundamental shortcomings in the synthesis of valuable ncAAs. Finally, 
we will discuss how directed evolution could provide future biocatalyst improvements.
2. Applications of ncAAs in chemistry, medicine, and biology
Even with advances like photo-redox chemistry, metal-catalyzed cross-coupling, and 
asymmetric catalysis, the bottleneck for drug discovery is chemical synthesis.2 Important 
pharmaceutical functionalities such as chiral amines, N-heterocycles, and unprotected polar 
groups are challenging to work with in synthesis, but the incorporation of ncAAs directly 
into synthetic pipelines can bypass many of these difficulties. For example, the diabetes 
medication saxagliptin (Scheme 2) contains a chiral amine as well as a challenging β-
quaternary center that is important for the drug’s activity.1 Improved methods to synthesize 
this drug have focused on producing the ncAA L-α−3-hydroxy-1-adamantyl-glycine 
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enzymatically for use as a building block in the synthesis of saxagliptin.6 Other medicines 
contain alkaloids, pharmaceutically important natural products derived from amino acids. 
Alkaloids and similar compounds make up many essential medicines such as dopamine 
(heart failure), codeine and morphine (analgesic), vincristine and irinotecan (cancer), and 
quinine (antimalarial).7 As biologically active and synthetically useful molecules, it is 
unsurprising that ncAAs are present in 12% of the 200 top-grossing drugs.8 Incorporating 
ncAAs and ncAA-derived products into synthetic pipelines allows important 
pharmaceuticals to be synthesized more easily than ever before. However, few ncAAs are 
readily available, and improved synthetic and biocatalytic methods are needed to realize 
their full potential.
Protein therapeutics including peptides and antibodies also make use of ncAAs. Therapeutic 
peptides have been used since the 1920s, when insulin was extracted from animal pancreases 
for diabetes treatment. Peptide drugs remain important to this day, with more than 60 
approved for use.1 However, most natural peptides are not suitable therapeutics because they 
are present only in low concentrations and are susceptible to proteolysis, limiting 
bioavailability. Incorporation of ncAAs with the D-configuration, unnatural backbones, or 
bulky side chains can reduce proteolysis, and modified side chains can tune biological 
specificity and pharmacokinetics.1 For example, cyclic antimicrobial peptides such as 
daptomycin disrupt the membranes of infectious microorganisms. Daptomycin incorporates 
the ncAAs kynurenine, ornithine, and (2S,3R)-methylglutamate, as well as three D-amino 
acids (Scheme 3).
Antibodies and antibody-drug conjugates (ADCs) are another class of protein therapeutics 
that benefit from access to ncAAs. ADCs are versatile therapeutics composed of a 
chemotoxic agent coupled via an amino acid linker to an antibody that specifically targets a 
cellular component with limited side effects.9 A common linker is a dipeptide composed of 
valine and the ncAA citrulline, which is cleaved in the lysosome to release the toxic 
‘payload’ (Fig 1). The linker and payload are typically attached to the antibody via non-
specific modifications of surface-exposed cysteine and lysine residues. With this non-
specific conjugation, the payload may be attached at different positions and in different 
concentrations, resulting in a heterogeneous drug whose pharmacokinetics, safety, and 
efficiency are not well-defined. Incorporation of ncAAs into ADCs can provide site-specific, 
bio-orthogonal attachment points for the linker, affording tunable and reproducible control 
over the payload concentration.9
Amino acid sequence dictates protein tertiary structure and affects protein function, 
localization, recognition, and post-translational modification. Consequently, incorporation of 
ncAAs at certain positions within a protein sequence can be used to modulate the physical 
and chemical properties of that protein. For example, global replacement of methionine with 
selenomethionine provides heavy atoms for X-ray crystallography,10 while replacement of 
amino acids with their fluorinated analogues can influence the substrate specificity and 
stability of enzymes.11 Furthermore, genetic code expansion permits the site-specific 
incorporation of ncAAs into proteins where promiscuous global replacement might be 
undesirable or impossible.3,10 For example, ncAAs with side chains such as the 
environmentally sensitive fluorophore 7-hydroxycoumarin, the metal chelator 2,2’-
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bipyridine, and the metal-binding fluorophore 8-hydroxyquinoline have unique properties 
that can be used to probe biomolecular interactions or induce metal-dependent assembly or 
fluorescence.12,13 Additionally, ncAAs with reactive unsaturated aliphatic, azido, and 
carbonyl side chains can be used as site-specific bio-orthogonal handles for chemical 
modification.14 The ability to selectively manipulate proteins through the incorporation of 
ncAAs promotes the understanding and engineering of protein stability, activity, and 
mechanism.
3. Methods for ncAA production
Although ncAAs are valuable chemical and biological tools, their applications are limited by 
inefficient routes of production. The most popular approaches, such as extraction from 
protein hydrolysate, fermentation, chemical synthesis, and biocatalysis fall short in terms of 
cost, yield, or scope.15–17 Extracting amino acids from hydrolyzed proteins is excellent for 
large-scale production, especially when sourced from inexpensive industrial byproducts such 
as hair, meat, or plants. However, this is only suitable for naturally occurring ncAAs with 
unique physicochemical properties that enable purification, such as reactive side chains or 
extreme pH stability.
Amino acids are also produced on a large scale by microorganisms that convert sugars and 
other feedstocks into the desired products.15 Bacterial strains of Escherichia coli or 
Corynebacterium glutamicum have been extensively engineered for efficient metabolism and 
mitigated stress response to enhance yields.18 Production by fermentation, however, requires 
an organism with the capacity to synthesize the ncAA. This is a major complication, since 
biosynthetic pathways for many ncAAs either give poor yields or are simply unknown.
Chemical synthesis can access numerous ncAAs by employing intermediates such as serine-
derived lactones, hydantoins, or aziridines (Scheme 4, blue).19,20 A significant benefit of 
chemical synthesis approaches is their broad applicability, allowing a variety of ncAAs to be 
produced from a single synthetic pipeline. Limitations are also apparent: chemical synthesis 
can be labor-intensive, utilize hazardous reagents and produce significant waste products, or 
generate racemic products that require further purification.
An increasingly useful approach to preparing ncAAs is biocatalysis, which can either 
replace or supplement chemical synthesis and fermentation with enzymes (Scheme 4, red).
4,16
 Enzyme-catalyzed reactions benefit from mild reaction conditions and a broad range of 
biocatalysts that can be used in derivatization or bond-forming reactions. For example, 
aminotransferases are used to form chiral amines by transferring the amino group of one 
amino acid to a prochiral α-keto acid while setting the stereochemistry at the α-carbon. The 
process for manufacturing Januvia, a diabetes drug, incorporates an engineered 
aminotransferase that replaces two steps of the chemical synthesis route.21 Other enzymes 
such as lyases capitalize on accessible, non-hazardous starting materials to synthesize 
diverse optically pure ncAAs. For example, ammonia lyases can catalyze the asymmetric 
amination of inexpensive, prochiral substrates such as fumarate or cinnamic acid derivatives 
to make optically pure ncAAs (discussed in Section 5.1).22,23 Other enzymes, such as 
tyrosine phenol lyase (TPL)24 and tryptophan synthase (TrpS),25,26 can generate more 
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complexity from even simpler substrates by coupling a nucleophilic side chain to an amino 
acid backbone (discussed in Section 5.2).
Although biocatalysts perform impressive chemical transformations, applications are limited 
by reaction and substrate scope as well as enzyme stability and compatibility with process 
conditions. Improved biocatalysts are needed for simple, green, and cost-effective access to 
a variety of ncAAs. Protein engineering can improve catalyst performance, expand the scope 
of substrates the enzymes can accept, and even generate new activities. Methods of directed 
enzyme evolution are especially powerful for rapid engineering. In the following sections of 
this review, we will focus on opportunities for engineering ncAA synthases that generate 
complex products from simple (e.g., prochiral or inexpensive) starting materials. We believe 
that these biocatalysts offer special advantages that will significantly improve the synthesis 
of ncAAs.
4. Enzyme engineering strategies
This review will illustrate several successful strategies for engineering improved ncAA 
synthases. Because the relationship between enzyme sequence and function is still largely 
unknown, we will focus primarily on methods in which collections of mutant enzymes—
called ‘libraries’—are generated and screened for desired properties. This process provides 
the basis for discovering beneficial mutations. A single round of mutation and screening is 
sufficient to engineer an improved enzyme as long as the library contains the improved 
variant and screening can accurately identify it. Indeed, several examples described in 
Section 5 describe enzymes that have shown substantial improvements in a single round of 
mutation and screening. However, accumulating mutations in iterations of mutagenesis and 
screening, an approach known as directed evolution, can produce even better enzymes. The 
mutagenesis and screening strategies are the foundation of enzyme engineering, and success 
in an engineering project rests on the appropriate selection of complementary methods.
The first step is to select an enzyme as the starting point, known as the ‘parent’ enzyme. 
Even poor baseline activity for the reaction of interest can be the foundation of a good 
evolved enzyme, provided improvements in activity can be measured reliably, as discussed 
below. If the starting activity is too low, it can be worthwhile to explore homologous 
enzymes as parents, as they can differ drastically in substrate scope, activity, and stability.27 
Enzymes with high stability are often preferred parents, especially for directed evolution, as 
they can support the accumulation of activating but often destabilizing mutations.28
Starting from the parent gene, diversity is introduced to produce a collection of mutant 
genes, which are used to transform a suitable host organism. Standard microbiology 
techniques are typically used to array individual clones—containing individual mutant genes
—into physically separated compartments, such as the wells of microtiter plates, where gene 
expression and protein production take place. The resulting library of enzyme variants is 
then assayed for the desired activity with an appropriate screen. (It should be noted that 
some screening techniques, such as those that use cell sorting instruments, as well as most 
types of selections, do not require that the cells containing the protein variants be physically 
separated prior to screening or selection, but instead rely on the technique itself to 
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accomplish separation. These methods, however, provide enrichment rather than full 
separation of individual clones.) The sensitivity and reproducibility of the screen determines 
the improvement that can be measured reliably and therefore discovered in these 
experiments, while the mutagenesis method determines the sequence diversity that is 
searched. Mutagenesis and screening methods should be evaluated together, as the 
combination is critical to the success of any enzyme engineering project. The goal is to 
generate libraries that are sufficiently rich in improved enzyme variants that the screening 
method can find them efficiently.
The first rule to remember when developing a protein engineering screen is: you get what 
you screen for. In other words, the screen needs to report faithfully on the desired property 
or set of properties. Developing a very high throughput screen for synthesis of a ncAA can 
be challenging, especially when the starting yield is low, and/or the product amino acid does 
not have a chromophore or fluorophore that make it readily visible in a complex medium 
with high concentrations of substrates and other species. Indirect assays, such as surrogate 
screens (see Section 5.1.2) or selections (a method of associating the fitness of an organism 
with the activity of an enzyme) can be used, but this can and often does result in variants that 
perform well in the surrogate screen or selection but not in the desired task; there are of 
course many notable successes. Additionally, if the assay requires purification steps or 
additional reactions, the throughput may be limited to a few hundred, rather than thousands, 
of samples per day. The sample throughput capacity and cost determine whether one has to 
take a more ‘designed’ approach to making variants or whether one can use more agnostic 
mutagenesis methods such as random mutagenesis of the whole sequence. Because new 
mutagenesis and library construction protocols appear regularly, we will not go into any 
detail on specific methodologies. Rather, we will discuss four general classes of library 
construction and the screening techniques commonly associated with them. Readers may be 
interested in recent reviews from the Hilvert29 and Liu30 groups for further details on 
selections and library construction methods.
The mutagenesis approach requiring the highest level of design is one in which the protein 
engineer has identified one or more specific residues that influence enzyme behavior and 
then decides which mutation to make at those residues using site-directed mutagenesis 
methods. Making informed decisions, however, usually requires detailed structural 
information, and success depends on having an accurate assessment of how a given mutation 
will affect biocatalyst structure and function. An example of site-directed mutagenesis is 
targeted modification of the active site to improve substrate access. Bulky residues (e.g., 
leucine or phenylalanine) in the active site may be mutated to smaller ones (e.g., alanine) to 
improve binding of larger substrates. Such ‘designed’ mutations can provide a starting point 
for further improvement by directed evolution or may even be sufficient to generate an 
efficient biocatalyst. Since this approach explores a very limited sequence space, success 
depends entirely on the validity of the hypothesis. It is important to keep in mind that failed 
attempts are rarely published.
A somewhat more agnostic approach is to use site-saturation mutagenesis to sample most or 
all possible mutations at a given residue or set of residues. Beneficial mutations found by 
screening saturation mutagenesis libraries can be accumulated in sequential rounds (see ref. 
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31 for further reading), by recombination (see below), or by screening combinatorially 
saturated mutant libraries. If positions are sampled one or two at a time, these libraries are 
small enough to be analyzed by techniques such as high-performance liquid chromatography 
(HPLC), gas chromatography (GC), mass spectrometry (MS), and even thin layer 
chromatograph (TLC) or nuclear magnetic resonance (NMR). Of course, success with site-
saturation mutagenesis depends on whether the engineer has chosen the right residue(s) to 
target. For many enzymes and properties this is not easy, and libraries at many positions may 
have to be screened in order to find beneficial mutations.
In directed evolution, random mutagenesis is often used to introduce mutations at a low 
frequency throughout the gene of interest. A great advantage of random mutagenesis is that 
no prior knowledge of the enzyme structure or mechanism is required: the experiment tells 
you what is important. For example, random mutagenesis and screening can identify 
mutations that mimic allosteric activation, which may be distributed throughout the protein.
32
 Random mutagenesis and screening often finds activating mutations that are distant from 
the active site or substrate binding pocket, at residues that would likely not be chosen by any 
‘design’ methods. (Examples of this can be seen in Section 5.2.2.) However, there are costs: 
many randomly-mutated variants are parent-like, or unaltered in the property screened, and 
therefore significant screening effort is required to identify the rare beneficial mutations. 
Often this means screening hundreds to thousands of samples. Furthermore, random 
mutagenesis by the most convenient method, error-prone PCR, only accesses a fraction of all 
the possible single amino acid substitutions (roughly 6 out of 19) as it traverses the codon 
table via single nucleotide mutations; at the low mutation rates used for directed evolution, 
there is an underwhelming probability of making two mutations within the same codon.
Recombination, performed either in vitro or in vivo, parallels the natural events of 
homologous recombination, such as the shuffling of chromosomal DNA during meiosis or 
diversity generation during V(D)J antibody recombination.33,34 Rather than generating new 
mutations, recombination navigates the evolutionary landscape by leveraging genetic 
diversity that already exists. One can recombine homologous protein sequences to make 
chimeric proteins or recombine previously identified mutations to create new combinations 
in a single sequence. The latter is useful when several beneficial mutations are found in one 
generation of random mutagenesis. Stemmer’s ‘DNA shuffling’ method35 and Zhao’s 
‘staggered extension’ method36 perform random mutagenesis and recombination in one 
operation. Sequence information is all that is necessary for most recombination methods.
In choosing a mutagenesis strategy, the goal is to find and accumulate beneficial mutations 
with the least combined mutagenesis and screening effort. Site-directed and site-saturation 
mutagenesis are highly focused approaches and produce small libraries that can be screened 
with relatively low-throughput techniques. The downside is that the targeted positions are 
limited and may not yield beneficial mutations. Random mutagenesis samples a far greater 
sequence space, but the frequency of beneficial mutations can be low, and a higher-
throughput screen is generally needed to find improvements. As any library is likely to 
contain variants exhibiting a range of performance, it is crucial to establish a robust 
screening system that discriminates improved enzyme variants from the parent.37 Improved 
variants can always be used for subsequent rounds of engineering in a directed evolution 
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approach. Making incremental improvements is an effective way to navigate the enzyme’s 
fitness landscape to create an exceptional enzyme for a given task; this evolutionary search 
process can even create entire lineages of enzymes that excel at different tasks (see Fig 9 in 
Section 5.2.2).
Although not discussed here, computational models are also showing promise for enzyme 
engineering, with small in silico libraries yielding high frequencies of activating mutations 
that reduce screening efforts. This typically requires identifying a parent enzyme with an 
appropriate and well-understood mechanism and then computationally redesigning that 
enzyme based on the desired mechanism. When used correctly, this approach can produce a 
slightly active enzyme for further evolution or can even create highly proficient biocatalysts, 
as demonstrated in a recent report from the Janssen and Wu groups on the development of β-
ncAA synthases.5 Importantly, it is now possible to order entire libraries of mutant genes 
made to individual specifications from various DNA suppliers. While expensive, synthetic 
libraries of individual genes reduce labor associated with library construction and validation 
and also reduce screening requirements compared to libraries made by various 
randomization methods.
5. Engineering improved ncAA synthases
In this section, we discuss examples where enzyme engineering principles described above 
have been applied to improve biocatalytic ncAA synthesis. These examples highlight key 
aspects of engineering proteins through mutation and screening to quickly achieve 
functional goals and cover different parent enzymes, mutation strategies, screening 
approaches, and reaction conditions.
5.1 Asymmetric carbon-nitrogen bond formation by ammonia lyases
Ammonia lyases catalyze reversible carbon-nitrogen bond cleavage to produce a trans-α,β-
unsaturated carboxylic acid and ammonia (Scheme 5).38 Of interest in this review are 
ammonia lyases that competently catalyze the reverse reaction, resulting in the asymmetric 
addition of ammonia to synthesize enantiopure α-amino acids. This occurs with readily 
available, prochiral substrates such as fumarate or cinnamic acid analogues. Ammonia is 
activated within the enzyme, either by internal residues or by a special electrophilic group, 
which facilitates nucleophilic attack at the electrophilic alkene followed by proton donation 
to the β-carbon by a catalytic base (Scheme 5). Ammonia lyases act on a diverse set of 
substrates, such as aspartate (aspartate ammonia lyases, or DALs), β-methylaspartate 
(MALs), and the aromatic amino acids (PALs, TALs, and HALs for phenylalanine, tyrosine, 
and histidine, respectively). This class of enzymes has the potential to access diverse types 
of functional ncAA products, from β-substituted aspartate analogues to aromatic ncAAs 
(also called arylalanines).
5.1.1 MAL: Accessing bulky β-substituted aspartate analogues.—Of all the 
ammonia lyases, those that act on aspartate and its analogues are among the most specific.38 
The MAL catalytic cycle requires the presence of a β-carboxylate (the aspartate side chain, 
labeled blue in Scheme 6), which renders the α-carbon electrophilic and provides necessary 
acidity at the β-carbon (labeled red in Scheme 6). In MALs, the species with the 
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electrophilic α-carbon (Scheme 6, rightmost resonance species) is further stabilized by a 
bound magnesium ion that coordinates the negatively charged β-carboxylate. Because of 
this, substitutions are better tolerated at the α-carboxylate group by MALs, enabling 
production of certain β-ncAAs rather than the corresponding α-ncAA that lacks the 
aspartate side chain (Scheme 7). This approach has recently been used with great success to 
computationally engineer an aspartate ammonia lyase for β-amino acid production.5 
Therefore, if used to synthesize α-ncAAs, MALs are best suited to synthesize aspartate 
analogues as they contain the necessary β-carboxylate.
Wild-type MALs can produce β-methylaspartate—their eponymous natural substrate—from 
the prochiral substrate 2-methylfumarate (Scheme 6, R = methyl). MALs show moderate 
activity on substrates with slightly larger β-substituents such as ethyl, propyl, and ethoxy 
groups.23 Unfortunately, some of the more valuable aspartate analogues, such as the 
excitatory neural ligand transporter inhibitor threo-3-benzyloxyaspartate, fail to show even 
trace activity with MAL, which is attributed to the large size of the β-substituent.
To improve the biocatalytic synthesis of bulkier β-branched aspartate analogues, Raj and 
colleagues engineered MAL from the bacterium Clostridium tetanomorphum (CtMAL).23 A 
crystal structure of β-methylaspartate in complex with CtMAL suggested that three residues, 
F170, Y356, and L384, were likely to sterically occlude the binding of substrates with larger 
β-substituents (Fig 3). The authors prepared three separate site-saturation mutagenesis 
libraries targeting these residues, hypothesizing that the active site could be modified to 
enable access by bulkier substrates. After expressing the corresponding CtMAL variants in 
E. coli, they screened for amination of the model bulky substrate 2-hexylfumarate, toward 
which the wild-type enzyme showed no detectible activity. The authors used an absorbance 
assay to screen for 2-hexylfumarate amination by monitoring the change in 270-nm 
absorbance in the reaction mixture over time. Due to the conjugation between the terminal 
carboxylate groups in fumarate analogues, the substrate absorbs strongly at 270 nm (shown 
in Scheme 6). Following substrate amination to produce an α-amino acid, this conjugation is 
broken and the absorbance at 270 nm is significantly decreased. Using this approach, the 
authors identified L384A as a beneficial mutation that increased the yield of β-
hexylaspartate from 0% to 85% (Table 1). The CtMAL L384A variant was also able to react 
with fumarate, 2-hexylfumarate, and 2-benzyloxyfumarate, giving nearly complete 
conversion within an hour at room temperature.
Chemical synthesis of β-branched aspartate analogues is challenging because, in addition to 
containing two carboxylic acid groups and a reactive amine, they are diastereomeric, having 
stereocenters at both the α- and β-carbon positions. CtMAL L384A preferentially produces 
the threo isomer from the prochiral substrate (Scheme 6), mirroring the native enzyme. This 
specificity enabled synthesis of the valuable therapeutic compound threo-3-
benzyloxyaspartate in >95% excess over the erythro isomer. However, varying degrees of 
diastereomeric excess (de) were seen for other substrates, especially for those that contained 
thioether bonds, such as 2-benzylthioaspartate (Table 1). Nonetheless, this rapid engineering 
of CtMAL to access therapeutically relevant, optically pure, diastereomeric aspartate 
analogues from prochiral starting materials demonstrates the utility of protein engineering in 
ncAA synthesis.
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5.1.2 PAL: Efforts to evolve a D-arylalanine synthase.—Aromatic ncAAs have 
diverse applications.1,3 This has made ammonia lyases with expansive aromatic substrate 
scopes, such as PALs, a prime target for application and for engineering.38 PALs natively 
catalyze the reversible decomposition of L-phenylalanine to trans-cinnamic acid and 
ammonia (Scheme 8). This is accomplished with the aid of the highly electrophilic 4-
methylidine-5-imidazolone (MIO) group, which is unique in that it is not formally a 
cofactor. Rather, it is formed intramolecularly from a short three-amino acid sequence within 
the active site, in a manner reminiscent of GFP chromophore maturation.38 In the synthetic 
direction, the electrophilic MIO group enables amination by activating ammonia for 
nucleophilic attack, forming a stereospecific carbon-nitrogen bond (Scheme 8). The catalytic 
base of PALs must be even stronger than that of the aspartate-specific ammonia lyases, as 
aryl side chains do not render the protons of the β-carbon as labile as carboxylate groups do. 
PALs are an example of productive wild-type ncAA synthases with broad arylalanine-
synthase activity that can be used to synthesize ncAAs in vitro. For example, wild-type 
PALs readily aminate halogenated cinnamic acids to generate the corresponding halogenated 
phenylalanine analogues.22
The Turner group has carried out extensive engineering of PAL from the cyanobacterium 
Anabaena variabilis (AvPAL) for straightforward arylalanine synthesis. AvPAL has a broad 
substrate scope and is able to synthesize many different types of L-arylalanines with high 
activity and enantioselectivity. However, it was noted that the enantioselectivity of the 
reaction is compromised with electron-deficient substrates, such as nitrocinnamic acid.39 
Further analysis suggested that these substrates go through a MIO-independent pathway. In 
this case, the enzyme is still required for proton abstraction at the β-carbon, but ammonia 
does not need to be activated by MIO for nucleophilic attack, due to the enhanced 
electrophilicity of the α-carbon (Scheme 9). The effect is strong enough to produce a 
racemic mixture whenever electron density is directed away from the electrophilic alkene, 
i.e., with para or ortho substitutions; meta-substituted substrates are less affected.
While this is an unfortunate side reaction of AvPAL, the L-α-amino acids have a privileged 
position in nature, and enzymes that interact with them are abundant. A biocatalytic toolbox 
is lacking for the D-configured amino acids, which are particularly useful in peptide-based 
therapeutics as they can reduce degradation in vivo (see Section 2). For example, the 
gonadotropin-releasing hormone antagonist cetrorelix contains three D-arylalanine ncAAs 
(Scheme 10). Therefore, this effect could potentially be leveraged as starting activity for the 
evolution of a D-arylalanine synthase.
To improve the practicality and efficiency of synthesizing D-arylalanine products, 
Parmeggiani and colleagues engineered AvPAL to increase its potential as a D-arylalanine 
synthase.40 Site-saturation mutagenesis libraries were prepared by targeting 48 residues near 
the active site that they hypothesized might influence the enantioselectivity of the reaction. 
To design a screen, the authors considered an approach similar to the MAL reaction 
discussed in Section 5.1.1, as the PAL reaction results in a wavelength change at 290 nm 
during the reaction. However, this approach does not report on the stereochemistry. 
Parmeggiani and colleagues addressed this by implementing an enzyme cascade that 
specifically interacted with D-amino acids, producing an intense color change. This would 
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only occur within E. coli colonies expressing an AvPAL variant with improved D-arylalanine 
synthase activity (Fig 4). This high-throughput technique afforded rapid sampling of ~5,000 
colonies, with numerous AvPAL variants showing significantly faster rates of D-arylalanine 
production.
However, the screen had an important drawback: it only reported on D-amino acid 
production and provided no information on the corresponding production of an L-amino 
acids that might be expected from the less enantioselective MIO-independent mechanism. 
Indeed, further examination demonstrated that the variants identified in the screen did not 
change the distribution of enantiomers; they simply produced a racemic mixture more 
rapidly. It is not clear that mutations at the 48 targeted residues actually failed to enrich D-
arylalanine production, because the screen only reported on an increase in D-arylalanine 
production, exactly as designed. For example, it could be the case that some mutants 
enriched for the D-isomer, but did so more slowly and were therefore not apparent in the 
screen. Additional controls to differentiate racemic from enantioenriched product formation 
could be implemented in future studies, but this would make an already complex screen even 
more complicated. A recent report by Zhu and colleagues demonstrated that a single active-
site mutation to AvPAL (N347A), introduced by site-directed mutagenesis, resulted in a 2.3-
fold enrichment in production of D-p-nitrophenylalanine over L-pnitrophenylalanine by 
influencing the stereoselectivity of the reaction within the enzyme.41 AvPAL-N347A may 
provide valuable starting activity for future directed evolution of an enantioselective D-
arylalanine synthase.
5.2 Synthesis of designer ncAAs through direct side chain addition to amino-acrylate 
intermediates
Ideally, a ncAA synthase would be modular, in that it would attach desired side chains to an 
amino acid backbone with perfect stereoselectivity. An advantage typically associated with 
chemical synthesis, modularity allows different pieces to be incorporated into a diverse array 
of products with the same technique (see Section 3, Scheme 4). The pyridoxal 5’-phosphate 
(PLP)-dependent enzymes tyrosine phenol lyase (TPL) and tryptophan synthase (TrpS) have 
this attractive feature. These enzymes catalyze the β-elimination of an L-amino acid 
substrate to form an electrophilic amino-acrylate intermediate (Fig 5a). The amino-acrylate 
is a versatile electrophile that allows diverse nucleophilic substrates to be incorporated as 
amino acid side chains to form new L-α-amino acids. Due to the range of acceptable 
nucleophiles, these enzymes are capable of C–C bond formation as well as C–N and C–S 
bond formation. These enzymes also act with perfect enantioselectivity, as the 
stereochemistry at the α-carbon is retained through proton abstraction and donation on the 
same face of the amino-acrylate by the active-site lysine.25
5.2.1 TPL: Active-site remodeling of tyrosine-analogue synthases.—Tyrosine 
phenol lyase (TPL) catalyzes the degradation of L-tyrosine (Tyr) to phenol, pyruvate, and 
ammonia through a β-elimination reaction (Figs 5b and 6). The reaction is readily reversible, 
and the addition of excess of ammonia and pyruvate shifts the equilibrium to favor Tyr 
production. This occurs by promoting the formation of the electrophilic amino-acrylate 
intermediate, which then reacts with phenol to form a C–C bond via an electrophilic 
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aromatic substitution mechanism.42 Phenol is nucleophilic at positions para and ortho to the 
electron-donating hydroxyl group, and the enzyme positions this substrate such that the C–C 
bond is formed exclusively at the para position.
TPL has been used for industrial-scale Tyr production as well as for the preparation of 
important ncAAs.18 As early as the 1970s, TPL was found to synthesize the therapeutic Tyr 
analogue L-DOPA directly from catechol, ammonia, and pyruvate (Fig 6, R1 = OH, R2 = H). 
Fluorotyrosine, used to study redox-active tyrosine residues, is also synthesized by TPL via 
addition of the corresponding fluorinated phenol (Fig 6).43 Unfortunately, wild-type TPL 
variants fail to produce Tyr analogues with substituents larger than fluorine; catechol seems 
to be the exception.
TPL variants have been engineered to expand the nucleophiles accepted in the reaction. For 
example, 3-methyltyrosine (3-MeTyr), an anticancer drug precursor, is synthesized through a 
three-step, low-yielding, racemic chemical synthesis with many protecting and deprotecting 
steps, followed by biocatalytic kinetic resolution.24 To improve synthesis of 3-MeTyr, 
Seisser and colleagues engineered TPL from the bacterium Citrobacter freundii (CfTPL), 
one of the most extensively studied TPL variants.24 Using site-directed mutagenesis, the 
authors targeted residues in the active site (F36, T125, M288, M379, and F448) that were 
hypothesized to interact unfavorably with substituted phenols (Fig 6). To reduce the steric 
restrictions, the hydrophobic residues were individually mutated to valine, while T125 was 
mutated to serine, and these variants were then screened by HPLC. While many of the 
mutations increased the production of 3-substituted phenols, the M379V variant was found 
to produce 3-MeTyr, 3-methoxyTyr (another anticancer precursor), and 3-chloroTyr (an 
atherosclerosis marker) with good yields (Fig 6, red).
Engineering efforts by the Wang group have expanded the capacity of CfTPL to synthesize 
designer ncAAs that can be incorporated into a protein and exhibit a specialized function. In 
two studies they used site-saturation mutagenesis and a thin-layer chromatography (TLC)-
based screen to identify CfTPL variants that could synthesize the desired ncAA. The first 
study focused on making 3-(methylthio)-L-tyrosine (MtTyr; Fig 6, purple), which is a Tyr-
Cys cofactor mimic.44 The Tyr-Cys cofactor is known to modulate enzyme kinetics and is 
common in metalloenzymes. However, Tyr-Cys cross-linking can only occur when the 
cysteine residue is positioned in a particular orientation relative to the tyrosine residue, 
which is difficult or impossible to engineer in many proteins. The authors reasoned that 
MtTyr might offer the properties of the Tyr-Cys cofactor in a single residue and that a TPL 
variant could be used to synthesize it in the laboratory. Wild-type CfTPL was selected as the 
parent for engineering a MtTyr synthase due to its well-characterized ability to generate 
other Tyr analogues.44 However, CfTPL had no activity toward the o-(methylthio)phenol 
nucleophile that forms the side chain of MtTyr. To accommodate MtTyr, Wang and 
colleagues individually targeted three active-site residues (F36, M228, and F448) for site-
saturation mutagenesis. The authors chose only 96 E. coli clones from these libraries for 
analysis using the TLC-based screen, which identified CfTPL F36L as having improved 
activity. This variant synthesized MtTyr with 40% yield at preparative scale, which could 
then be purified and incorporated into proteins of interest using an evolved orthogonal 
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amino-acyl tRNA synthetase and amber stop codon suppression technology (as described in 
ref. 10).
In a following study, the Wang group engineered CfTPL to synthesize the Tyr analogue 2-
amino-3-(8-hydroxy-5-quinolinyl)-L-alanine (HqAla; Fig 6, purple).12 HqAla contains the 
bidentate metal chelator 8-hydroxyquinoline (8-HQ) as its side chain. 8-HQ is a common 
organic ligand of metal complexes noted for its high quantum yield of fluorescence, 
particularly when bound to zinc(II). Wild-type CfTPL again had no activity with the desired 
nucleophile (8-HQ), so the authors repeated site-saturation mutagenesis targeting active site 
residues F36, M228, and P448. This study targeted all three sites simultaneously, generating 
a library of 4,096 possible variants. CfTPL variants were again analyzed by TLC, and 1024 
clones were screened to identify the double active-site mutant M228S/F448C that produced 
HqAla with 40% yield. Again, the synthesis of the ncAA was sufficient for downstream 
experiments and could be used to create proteins that exhibited zinc-dependent fluorescence, 
highlighting the capacity of enzyme engineering to access new chemical and biological 
space rapidly and effectively.
One mechanistic limitation of TPL is that the reaction is under thermodynamic control. The 
forward and reverse reaction rates of the net reaction depend strongly on the concentrations 
of products and reactants, and excess reactants are needed to drive product formation. 
Ammonia lyases (discussed in Section 5.1) also have this limitation, as do 
aminotransferases. The need for excess reagents is not a major issue when using TPL and 
ammonia lyases for preparative-scale synthesis, since ammonia and pyruvate are inexpensive 
and easy to exclude during purification. Nonetheless, it would be preferable to have the 
reaction under kinetic control such that product formation is effectively irreversible, 
improving atom economy and making in vivo applications more accessible. This type of 
reaction is possible when using CfTPL with specialized substrates. For example, S-(o-
nitrophenyl)-L-cysteine can undergo rapid β-elimination in the presence of CfTPL, as the 
nitrothiophenol side chain acts as a good leaving group (Fig 7).42 This subsequently forms 
the reactive amino-acrylate intermediate, which is attacked by phenol to produce Tyr. 
Furthermore, because CfTPL binds S-(o-nitrophenyl)-L-cysteine more tightly than Tyr, as 
long as S-(o-nitrophenyl)-L-cysteine is present in the reaction it preferentially undergoes β-
elimination and inhibits Tyr degradation. This approach gives yields of ~70%.
5.2.2 TrpB: Evolution of stand-alone TrpB function from an allosteric TrpS 
complex.—Due to the reversible nature of enzymatic reactions under thermodynamic 
control, the ncAA synthases discussed thus far have suffered from inherently low substrate 
coupling efficiencies, with a high concentration of one or more substrates remaining upon 
reaching equilibrium. Although there are ways to circumvent this by using specialized 
substrates, an ideal biocatalyst would couple stoichiometric proportions of simple substrates 
at high rates and with quantitative yields. Additionally, these biocatalysts could have 
applications in vivo, as physiological concentrations of reactants could be sufficient to form 
products. To accomplish this, the enzymatic reaction should be under kinetic control. This is 
the case for tryptophan synthase (TrpS), which catalyzes the final steps of L-tryptophan (Trp) 
biosynthesis.
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TrpS a heterodimeric complex composed of an α-subunit (TrpA) that allosterically regulates 
the β-subunit (TrpB).25 In the native reaction, indole glycerol-3-phosphate undergoes a 
retro-aldol reaction in TrpA to release indole. This induces TrpB to catalyze the β-
elimination of L-serine (Ser), which generates the amino-acrylate intermediate (Fig 8a). 
Indole then diffuses through a hydrophobic tunnel connecting the subunits and attacks the 
amino-acrylate to form Trp (Fig 8b). The wild-type TrpS enzyme can perform this C–C 
bond-forming reaction with an array of indole analogues in vitro, synthesizing substituted 
Trp analogues in a single step.25 Numerous Trp derivatives have been made using this 
strategy. For example, the Goss group demonstrated that Salmonella enterica TrpS can use 
7-chloroindole and Ser to form 7-chloroTrp, part of the antibiotic rebeccamycin (Scheme 
11a).45 This reaction occurs in a single step, whereas nature would require an additional Trp 
halogenase to add the chloro substituent to Trp. Additionally, nonindole nucleophiles have 
been used to form C–S and C–N bonds, demonstrating that TrpS can also be a platform for 
the production L-cysteine and L-β-aminoalanine ncAAs.25
Although TrpS is an impressive biocatalyst, there are roadblocks for its application. 
Expression of the TrpS complex is metabolically challenging for the host cell, and the need 
for both the TrpA and TrpB subunits complicates expression and engineering. TrpB 
performs the synthetically interesting β-substitution reaction between indole and Ser to 
generate Trp, while TrpA generates indole in situ so that this toxic metabolite is not released 
into the cytosol. If the indole analogues are added exogenously, then TrpA is superfluous, 
but removing TrpA significantly decreases the activity of TrpB, due to the allosteric 
interactions between the subunits of TrpS.26
Buller and colleagues engineered a stand-alone TrpB ncAA synthase by directed evolution 
of TrpB from the hyperthermophilic archaeon Pyrococcus furiosus (PfTrpB; evolution 
shown in Fig 9, red).26 Because it was unknown whether directed evolution could recover 
the activity lost by removal of TrpA and, if so, what mutations would be beneficial, Buller 
used random mutagenesis to evolve the stand-alone PfTrpB. Variants were screened for Trp 
formation by monitoring an increase in 290-nm absorption, caused by a slight red-shift in 
the absorption of indole as it is converted to Trp. Impressively, nearly 4% of the 528 first-
generation variants of PfTrpB screened displayed an increase in Trp formation. This is a 
higher rate of beneficial mutations than is usually seen in a random mutagenesis experiment 
and shows that there are many possible ways to reactivate TrpB. The greatest single 
improvement came from a T292S mutation that restored the kcat to that of wild-type PfTrpS 
(PfTrpB2G9, which we will simplify to Pf2G9). An additional five mutations (P12L, E17G, 
I68V, F274S, and T321A) resulted in a PfTrpB variant whose kcat exceeded that of the wild-
type TrpB threefold (Pf0B2). Interestingly, none of these six beneficial mutations were in the 
active site, but rather were distributed throughout the TrpB structure. Further analysis 
showed that these mutations recapitulate the action of TrpA and stabilize the enzyme’s 
‘closed’ conformation, a state that promotes formation of the reactive amino-acrylate 
intermediate.32
After establishing a stand-alone PfTrpB platform, Buller’s team engineered catalysts for 
making β-methyltryptophan (β-MeTrp) analogues.46 The ncAA β-MeTrp is a component of 
biologically important molecules such as indolmyin and streptonigrin (Scheme 11b). The 
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presence of two adjacent stereocenters makes chemical synthesis of β-MeTrp challenging, 
but biocatalysts exhibit powerful spatial control over the diastereomeric configuration (see 
Section 5.1.1). Thus, it was reasoned that using the β-branched substrate L-threonine (Thr) 
might enable production β-MeTrp in a single step. This would be especially useful if the 
chirality—which is lost at both the α and β positions upon amino-acrylate formation—could 
be retained in the product (Scheme 12). (For clarity, we will refer to the β-substituted amino-
acrylate intermediates simply as amino-acrylates.) Furthermore, it would be a significant 
simplification over the natural β-MeTrp biosynthetic pathway, which starts with Trp and 
recruits an additional three enzymes for methylation at the β-position. Although wild-type 
PfTrpS has been shown to use Thr as a substrate, this process is highly inefficient. When 
indole glycerol-3-phosphate is used as the source of indole, the enzyme shows a >82,000-
fold preference for Ser over Thr.47
To encourage activity with Thr, Herger et al. applied random mutagenesis and recombination 
to the stand-alone variant Pf4D11.46 Following two rounds of mutagenesis and screening for 
(2S,3S)-β-methyltryptophan (β-MeTrp) formation at 290 nm from a mixture with Thr and 
indole, a new variant (Pf2B9) was identified that incorporated three mutations (Fig 9, 
orange). Pf2B9 boosted production of β-MeTrp >6,000-fold relative to wild-type PfTrpB. 
Furthermore, Pf2B9 accepted an array of indole substrates: seven (2S,3S)-β-MeTrp 
analogues were synthesized on preparative scale with >99% de. While the formation of Trp 
analogues is irreversible, PfTrpB was found to be limited by the unproductive abortive 
deamination of the amino-acrylate intermediate (Fig 8c), which consumes an equivalent of 
amino acid substrate. However, adding excess Ser or Thr to the reaction can reduce this 
effect and improve Trp production, albeit with lower coupling efficiency.
Next, Boville and colleagues sought to expand the substrate scope of PfTrpB to synthesize 
more complex β-branched ncAAs, such as (2S,3S)-β-ethyltryptophan (β-EtTrp) and (2S,
3S)-β-propyltryptophan (β-PrTrp) (Fig 9, pink).48 Pf2B9 was selected as the parent enzyme 
due to its activity with Thr, but even this evolved variant had poor baseline activity with (2S,
3R)-β-ethylserine (β-EtSer) and (2S,3R)-β-propylserine (β-PrSer). Modeling β-EtSer into 
the Pf2B9 active site suggested that residue L161 clashed with the bulkier β-ethyl 
substituent. Based on the hypothesis that a smaller side chain would reduce steric 
hinderance, L161 was mutated to alanine (Pf2B9 L161A), which proved to increase activity 
with indole and β-ethylserine. Two rounds of random mutagenesis and screening for 
increased absorption at 290 nm generated a variant with two additional beneficial mutations 
(Pf8C8), which was then used as the parent for recombination with eight previously 
identified mutations. This final variant, Pf7E6, was found to be a robust biocatalyst for four 
amino acid substrates (Ser, Thr, β-EtSer, β-PrSer) and ten indole analogues, which enabled 
Boville and coworkers to generate dozens of β-branched ncAAs. Mechanistic studies 
showed that the versatility of Pf7E6 arose from a more stable amino-acrylate than found in 
Pf2B9. This further reduced the frequency of the unproductive deamination reaction, and 
single equivalents of substrate could be used to achieve high yields.48
Many desirable ncAAs still remained inaccessible using TrpS and the evolved TrpBs. In 
particular, bulky or electron-deficient indoles, particularly 4-substituted indoles, remained 
challenging substrates; bulky groups introduce additional steric factors that interfere with 
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substrate positioning, while electron-withdrawing groups attenuate nucleophilicity (Scheme 
13). To address this, Romney and colleagues targeted production of 4-nitroTrp,49 one of the 
most difficult products for PfTrpB and a valuable precursor in the synthesis of tumor-
promoting indolactam V and the natural herbicide thaxtomin A (Scheme 14). Multiple 
rounds of random mutagenesis and recombination identified the variant Pf2A6, which 
increased the yield of 4-nitroTrp to 95% (Fig 9, green). To improve the sensitivity of the 
screen during the evolution, Romney and colleagues implemented an organic extraction step 
to quickly and reliably remove excess nitroindole from the aqueous media, reducing the 
background signal of the colorimetric screen. While Pf2A6 was most active with 4-nitroTrp, 
it was observed that the early mutations M139L and N166D were broadly activating for 4-, 
5-, 6-, and 7-nitroTrp, while the later mutations were specific to 4-nitroTrp. Results of 
assaying for pyruvate formation suggested that this early general improvement was due to 
further stabilization of the amino-acrylate intermediate, which was not as readily hydrolyzed 
and thus more available for attack by weakly nucleophilic substrates.
Through additional directed evolution, Romney et al. engineered PfTrpB for high activity 
toward 4-, 6-, and 7-nitroindole.49 However, the available variants were still poorly active 
with 5-nitroindole, as well as many other 4-, and 5-substituted indoles. Murciano-Calles et 
al. had previously shown that the activating mutations found in PfTrpB could be transferred 
to TrpBs isolated from other species, such as the hyperthermophilic bacterium Thermotoga 
maritima (TmTrpB).27 Despite being from different orders of life and having only 64% 
sequence identity, many of the activating mutations found in PfTrpB were also beneficial 
when made at the corresponding residues in TmTrpB, suggesting that both of these TrpS 
complexes were regulated using similar allosteric mechanisms. However, these enzymes 
displayed varied activity with different substituted indoles: PfTrpB was the best for many 6- 
and 7-substituted Trp analogues, while TmTrpB was superior for many 4- and 5-
substitutions (Fig 9, blue). Romney and colleagues capitalized on this discovery and used 
both PfTrpB and TmTrpB variants to synthesize challenging nitroTrps, cyanoTrps, haloTrps, 
and di-substituted Trps.49 This work culminated in a panel of biocatalysts tuned to the 
substrates of interest. More than 20 Trp analogues could be prepared with good yields (ten 
exceeded 90% yield) from equimolar amounts of substrates and with low biocatalyst 
loadings.
Certain valuable Trp analogues still proved difficult to synthesize with the expanded TrpB 
platform, including 4-cyanoTrp, a blue-fluorescent ncAA useful for in vitro and in vivo 
imaging. In a single round of random mutagenesis followed by recombination, Boville et al. 
identified variant Tm9D8*, which improved yields of 4-cyanoTrp from 24% to 78% (Fig 9, 
purple).50 Intriguingly, the mutations in Tm9D8* shifted the temperature profile of the 
biocatalyst to lower temperature. Previously, the thermophilic TrpB variants showed peak 
performance at 75 °C. However, Tm9D8* achieves 76% yield at 37 °C, while at 75 °C only 
46% yield is achieved. Furthermore, this temperature shift occurs without decreasing the 
thermostability of the enzyme, which is still active after heat-treatment above 90 °C. The 
high stability facilitates purification from mesophilic hosts like E. coli, as demonstrated by 
the gram-scale production of 4-cyanoTrp using heat-treated lysate. The high activity at lower 
temperature also creates potential in vivo applications.
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6. Conclusions and Future Directions
Noncanonical amino acids are valuable as final products and intermediates, and enzymes 
provide a straightforward, cost-effective, and green method for their production. These 
enzymes can be optimized for activity, selectivity, stability and other important properties. 
Enzymes such as ammonia lyases, tyrosine phenol lyase, and tryptophan synthase can 
perform reactions on substrates well beyond their natural activities and produce optically 
pure ncAAs from simple and inexpensive starting materials. However, only a few select 
classes of enzymes have been engineered to date; there is still a need for new classes of 
ncAA synthases that access an even wider range of amino acids.
Engineering useful new ncAA synthases requires suitable starting enzymes. Well-
characterized enzymes often serve as the basis for engineering new reactions, but 
homologous and even previously uncharacterized enzymes allow protein engineers to access 
a wealth of untapped functional and sequence diversity. Information gained from 
engineering one enzyme can be transferred to other family members. Beneficial mutations 
found in PfTrpB, as discussed in Section 5.2.2, were often beneficial when transferred to 
homologous TrpB enzyme subunits from other, even distantly related species. These variants 
had notable and useful differences in their substrate scopes, which facilitated further 
evolution.49 Future work can identify new enzymes in natural biosynthetic pathways that can 
be exploited for ncAA synthesis and serve as a launchpad for further evolution.
In addition to identifying new enzymes, it is important to explore previously studied variants 
and report on more complete substrate scopes rather than just a few key substrates. This can 
help inform the enzyme’s mechanism and function and facilitates the selection of even better 
parent enzymes in future engineering. For example, Wang’s group could have used Seisser’s 
CfTPL-M379V variant24 as the parent for engineering activity for MtTyr production,44 as 3-
methoxyTyr and MtTyr are structurally similar. Alternatively, Seisser and coworkers could 
have reported MtTyr and other Tyr analogue activity with their CfTPL variant, which would 
have provided additional information on how small alterations influenced the reactivity of 
the enzyme, if at all. Such information allows researchers to better traverse the vast and 
diverse landscape of protein function; stopping at a single beneficial mutation or product is 
shortsighted and leaves behind important opportunities.
With new discoveries and unbridled engineering, nature’s remarkable biosynthetic 
machinery has the potential to change how we approach chemistry, biology, and medicine. 
Enzymes such as ncAA synthases have proven to be potent and malleable biocatalysts, and 
protein engineering is sure to bring more versatile tools into the fold.
Acknowledgements
The authors would like to thank Dr. Sabine Brinkmann-Chen, Dr. David Romney, Prof. Andrew Buller, and Bradley 
Boville for helpful discussion and comments on the manuscript. C.E.B. was supported by a postdoctoral fellowship 
from the Resnick Sustainability Institute. This work was funded by the Jacobs Institute for Molecular Engineering 
for Medicine (Caltech) and the Rothenberg Innovation Initiative (formerly CI2).
Almhjell et al. Page 17
Chem Soc Rev. Author manuscript; available in PMC 2019 December 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
References
1. Blaskovich MAT, J. Med. Chem, 2016, 59, 10807–10836. [PubMed: 27589349] 
2. Blakemore DC, Castro L, Churcher I, Rees DC, Thomas AW, Wilson DM and Wood A, Nat. Chem, 
2018, 10, 383–394. [PubMed: 29568051] 
3. Young DD and Schultz PG, ACS Chem. Biol, 2018, 13, 854–870. [PubMed: 29345901] 
4. Xue Y-P, Cao C-H and Zheng Y-G, Chem. Soc. Rev, 2018, 47, 1516–1561. [PubMed: 29362736] 
5. Li R, Wijma HJ, Song L, Cui Y, Otzen M, Tian Y, Du J, Li T, Niu D, Chen Y, Feng J, Han J, Chen 
H, Tao Y, Janssen DB and Wu B, Nat. Chem. Biol, 2018, 14, 664–670. [PubMed: 29785057] 
6. Park ES and Shin JS, J. Mol. Catal. B Enzym, 2015, 121, 9–14.
7. Ehrenworth AM and Peralta-Yahya P, Nat. Chem. Biol, 2017, 13, 249–258. [PubMed: 28199297] 
8. McGrath NA, Brichacek M and Njardarson JT, J. Chem. Educ, 2010, 87, 1348–1349.
9. Thu T, Nguyen H, Bai X and Shim H, Biodesign, 2015, 3, 154–161.
10. Liu CC and Schultz PG, Annu. Rev. Biochem, 2010, 79, 413–444. [PubMed: 20307192] 
11. Odar C, Winkler M and Wiltschi B, Biotechnol. J, 2015, 10, 427–446. [PubMed: 25728393] 
12. Liu X, Li J, Hu C, Zhou Q, Zhang W, Hu M, Zhou J and Wang J, Angew. Chemie Int. Ed, 2013, 
52, 4805–4809.
13. Almhjell PJ and Mills JH, Curr. Opin. Struct. Biol, 2018, 51, 170–176. [PubMed: 29980106] 
14. Boutureira O and Bernardes GJL, Chem. Rev, 2015, 115, 2174–2195. [PubMed: 25700113] 
15. D’Este M, Alvarado-Morales M and Angelidaki I, Biotechnol. Adv, 2018, 36, 14–25. [PubMed: 
28888551] 
16. Rudroff F, Mihovilovic MD, Gröger H, Snajdrova R, Iding H and Bornscheuer UT, Nat. Catal, 
2018, 1, 12–22.
17. Völler JS and Budisa N, Curr. Opin. Biotechnol, 2017, 48, 1–7. [PubMed: 28237511] 
18. Lütke-Eversloh T, Santos CNS and Stephanopoulos G, Appl. Microbiol. Biotechnol, 2007, 77, 
751–762. [PubMed: 17968539] 
19. Ager DJ, in Amino Acids, Peptides, and Proteins in Organic Chemistry, Vol. 1 - Origins and 
Synthesis of Amino Acids, ed. Hughes AB, WILEY-VCH, 2009, pp. 495–526.
20. Brittain WDG and Cobb SL, Org. Biomol. Chem, 2018, 16, 10–20.
21. Slabu I, Galman JL, Lloyd RC and Turner NJ, ACS Catal, 2017, 7, 8263–8284.
22. Gloge A, Zon J, Kovari A, Poppe L and Rétey J, Chem. Eur. J, 2000, 6, 3386–3390. [PubMed: 
11039531] 
23. Raj H, Szymański W, De Villiers J, Rozeboom HJ, Veetil VP, Reis CR, De Villiers M, Dekker FJ, 
De Wildeman S, Quax WJ, Thunnissen AMWH, Feringa BL, Janssen DB and Poelarends GJ, Nat. 
Chem, 2012, 4, 478–484. [PubMed: 22614383] 
24. Seisser B, Zinkl R, Gruber K, Kaufmann F, Hafner A and Kroutil W, Adv. Synth. Catal, 2010, 352, 
731–736.
25. Phillips RS, Tetrahedron Asymmetry, 2004, 15, 2787–2792.
26. Buller AR, Brinkmann-Chen S, Romney DK, Herger M, Murciano-Calles J and Arnold FH, Proc. 
Natl. Acad. Sci. U. S. A, 2015, 112, 14599–14604. [PubMed: 26553994] 
27. Murciano-Calles J, Romney DK, Brinkmann-Chen S, Buller AR and Arnold FH, Angew. Chemie 
Int. Ed, 2016, 55, 11577–11581.
28. Bloom JD, Labthavikul ST, Otey CR and Arnold FH, Proc. Natl. Acad. Sci. U. S. A, 2006, 103, 
5869–5874. [PubMed: 16581913] 
29. Zeymer C and Hilvert D, Annu. Rev. Biochem, 2018, 87, 131–157. [PubMed: 29494241] 
30. Packer MS and Liu DR, Nat. Rev. Genet, 2015, 16, 379–394. [PubMed: 26055155] 
31. Reetz MT and Carballeira JD, Nat. Protoc, 2007, 2, 891–903. [PubMed: 17446890] 
32. Buller AR, van Roye P, Cahn JKB, Scheele RA, Herger M and Arnold FH, J. Am. Chem. Soc, 
2018, 140, 7256–7266. [PubMed: 29712420] 
33. Heyer WD, Cold Spring Harb. Perspect. Med, 2015, 5, 1–24.
34. Briney BS and Crowe JE, Front. Immunol, 2013, 4, 1–7. [PubMed: 23355837] 
Almhjell et al. Page 18
Chem Soc Rev. Author manuscript; available in PMC 2019 December 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
35. Stemmer WP, Proc. Natl. Acad. Sci, 1994, 91, 10747–10751. [PubMed: 7938023] 
36. Zhao H, Giver L, Shao Z, Affholter JA and Arnold FH, Nat. Biotechnol, 1998, 16, 258–261. 
[PubMed: 9528005] 
37. Zhang J-H, Chung TDY and Oldenburg KR, J. Biomol. Screen, 1999, 4, 67–73. [PubMed: 
10838414] 
38. Parmeggiani F, Weise NJ, Ahmed ST and Turner NJ, Chem. Rev, 2018, 118, 73–118. [PubMed: 
28497955] 
39. Lovelock SL, Lloyd RC and Turner NJ, Angew. Chemie Int. Ed, 2014, 53, 4652–4656.
40. Parmeggiani F, Lovelock SL, Weise NJ, Ahmed ST and Turner NJ, Angew. Chemie Int. Ed, 2015, 
54, 4608–4611.
41. Zhu L, Feng G and Ge F, Appl. Biochem. Biotechnol, DOI:10.1007/s12010-018-2794-3.
42. Phillips RS, Chen HY and Faleev NG, Biochemistry, 2006, 45, 9575–9583. [PubMed: 16878992] 
43. Seyedsayamdost MR, Yee CS and Stubbe J, Nat. Protoc, 2007, 2, 1225–1235. [PubMed: 
17546018] 
44. Zhou Q, Hu M, Zhang W, Jiang L, Perrett S, Zhou J and Wang J, Angew. Chemie Int. Ed, 2013, 52, 
1203–1207.
45. Smith DRM, Willemse T, Gkotsi DS, Schepens W, Maes BUW, Ballet S and Goss RJM, Org. Lett, 
2014, 16, 2622–2625. [PubMed: 24805161] 
46. Herger M, Van Roye P, Romney DK, Brinkmann-Chen S, Buller AR and Arnold FH, J. Am. Chem. 
Soc, 2016, 138, 8388–8391. [PubMed: 27355405] 
47. Buller AR, Van Roye P, Murciano-Calles J and Arnold FH, Biochemistry, 2016, 55, 7043–7046. 
[PubMed: 27935677] 
48. Boville CE, Scheele RA, Koch P, Brinkmann-Chen S, Buller AR and Arnold FH, Angew. Chemie 
Int. Ed, DOI: 10.1002/anie.201807998.
49. Romney DK, Murciano-Calles J, Wehrmüller J and Arnold FH, J. Am. Chem. Soc, 2017, 
139,10769–10776. [PubMed: 28708383] 
50. Boville CE, Romney DK, Almhjell PJ, Sieben M and Arnold FH, J. Org. Chem, 2018, 83, 7447–
7452. [PubMed: 29651849] 
Almhjell et al. Page 19
Chem Soc Rev. Author manuscript; available in PMC 2019 December 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig 1. 
Antibody-drug conjugates (ADCs) target drugs to specific locations through the high-affinity 
interactions of the antibody to its antigen. In this simple example, the drug is attached to an 
antibody by site-specific incorporation of the ncAA selenocysteine (which can react with 
maleimides under different conditions than cysteine) and a cleavable valinecitrulline linker 
(blue). The drug is released following cleavage of the linker (indicated with a red dashed 
line).
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Fig 2. 
Protein engineering by mutagenesis and screening. A successful engineering strategy 
depends on the choice of starting enzyme (the ‘parent’ enzyme), the mutation strategy, and 
the screening approach. A good choice of parent enzyme is typically one that already 
exhibits that desired activity (but poorly), or an enzyme that performs a mechanism that is 
compatible with that activity. Homologous enzyme variants can also be worthwhile to test, 
as are thermophilic enzymes. After parent selection, an appropriate mutagenesis technique is 
applied to the parent gene. Depending on the amount of information known and the 
functional goals, site-directed or site-saturation mutagenesis can target a single position of 
the enzyme, while random mutagenesis can blindly explore the entire sequence, and 
recombination can combine known activating mutations or swap genetic diversity between 
different variants. Following this, the choice of mutation strategy will largely influence the 
choice of screening technique. Colorimetric screens (illustrated here) are wise choices for 
large libraries, while smaller libraries can be screened with lower-throughput techniques, 
such as HPLC. Once an improved variant is—or multiple improved variants are—identified, 
the cycle can be repeated, which is called directed evolution. Depending on the results, the 
same mutation strategy and screen can be used, or an entirely new approach can be adopted 
if appropriate.
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Fig 3. 
Engineering the active site of MAL from Clostridium tetanomorphum (CtMAL) to tolerate 
larger substrates. A crystal structure of CtMAL (PDB ID: 1KKR) in complex with its native 
ncAA substrate β-methylaspartate (white) suggested that three bulky residues (orange) 
might restrict the size of the β-substituent that could productively bind in the active site. The 
β-substituent and targeted residues are shown with space-filling spheres to illustrate the 
steric requirements of the active site, and the magnesium ion (purple) and catalytic base 
(K331) are also shown. Site-saturation mutagenesis of these residues identified one mutation
—L384A—that greatly enhanced the ncAA activity of CtMAL.23
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Fig 4. 
Enhanced enantiomer detection via an enzyme cascade. A D-amino acid oxidase (DAAO) 
can be used to generate H2O2 from the D-arylalanine product. Horseradish peroxidase (HRP) 
uses H2O2 to oxidize colorless 3,3‘-diaminobenzidine (DAB), forming an orange-brown 
dye. While this screen successfully identified AvPAL variants that produced D-arylalanines 
at an increased rate, it failed to find variants that could produce enriched mixtures of D-
arylalanines over L-arylalanines.40
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Fig 5. 
(a) Generalized reaction for pyridoxal 5’-phosphate (PLP)-dependent ncAA synthesis. 
Simplified reactions that follow the overall scheme in (a) are shown for the PLP-dependent 
enzymes (b) tyrosine phenol lyase (TPL) and (c) the β-subunit of tryptophan synthase 
(TrpB).
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Fig 6. 
Expanding the substrate scope of TPL from Citrobacter freundii (CfTPL) through enzyme 
engineering. The wild-type enzyme shows activity only with phenol, catechol (3-
hydroxyphenol), and various fluorophenols to synthesize the corresponding tyrosine (Tyr) 
analogue. A crystal structure of CfTPL (PDB: 2YCN) in complex with the ncAA 3-
fluoroTyr (wild-type activity, R1 = F, R2 = H) suggests that the active site is packed with 
hydrophobic residues that might sterically occlude larger substituents on the phenolic 
substrate. Based on this hypothesis, Seisser et al. in 2010 targeted five residues in the active 
site to replace with valine (F36V, M288V, M379V, F448V) or serine (T125S) and identified 
the variant CfTPL-M379V, which could produce 3-methylTyr, 3-methoxyTyr, and 3-
chloroTyr.24 Two 2013 studies from the Wang group targeted three of these residues (F36, 
M288, and F448) with site-saturation mutagenesis to identify variants that could synthesize 
the ncAAs 3-(methylthio)-L-tyrosine (MtTyr, a Tyr-Cys cofactor mimic, provided by F36L 
mutation; blue)44 and 2-amino-3-(8-hydroxy-5-quinolinyl)-L-alanine (HqAla, a metal-
chelating ncAA, provided by double mutant M288S/F448C; purple).12
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Fig 7. 
The use of a specialized substrate, S-(o-nitrophenyl)-L-cysteine, affords kinetic control over 
Tyr production with CfTPL. This substrate binds in the active site (1) and rapidly forms the 
amino-acrylate (2), due to the good leaving group at the β-carbon (blue). The amino-acrylate 
(red) can either undergo nucleophilic attack by phenol (3, green) or deaminate to pyruvate 
and ammonia (4). Since TPL has a higher affinity for the substrate, S-(o-nitrophenyl)-L-
cysteine, than for the Tyr product (5), TPL selectively binds the substrate, thereby reducing 
degradation of the Tyr product and providing higher yields.
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Fig 8. 
The reaction of TrpB is under kinetic control, and parallels that of TPL with specialized 
substrates (as shown in Fig 7). (a) Formation of the reactive amino-acrylate intermediate 
(red) is favored by the β-elimination of L-serine and exclusion of water (blue) from the 
hydrophobic active site. (b) Indole (green) is activated for nucleophilic attack within the 
active site to form tryptophan (Trp); little to no β-elimination of Trp occurs when the 
enzyme is provided with Trp as its only substrate,32 suggesting that this step is effectively 
irreversible. (c) Nonproductive deamination of the amino-acrylate produces pyruvate and 
ammonia, a step that has been disfavored throughout the directed evolution of TrpB variants.
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Fig 9. 
Evolutionary lineage of TrpB-based ncAA synthases. Starting with the isolated TrpB 
enzyme subunit from Pyrococcus furiosus (PfTrpB), directed evolution has been used to 
improve standalone Trp production (red),26 as well as activity with L-threonine (orange),46 
substituted indoles (green and blue),49 and bulkier β-branched L-serine analogues (pink).48 It 
has also been engineered to produce Trp analogues such as 4-cyanoTrp at lower 
temperatures (purple).50 Intermediate variants in the evolution are shown as nodes, with 
representative variants shown with their structural models. Nodes are connected by lines that 
represent the mutagenesis approach. Transfer of activating mutations to a homologous TrpB 
from Thermotoga maritima (TmTrpB) resulted in variants that exhibited different substrate 
preferences than PfTrpB variants; where PfTrpB was adept at 6- and 7-substituted Trp 
production, TmTrpB was adept at 4- and 5-substituted Trp production. (Nomenclature notes: 
Pf2B9‡ is Pf2B9 with three mutations: L161V, M139L, L212P; Tm2F3-I184F is shortened 
to Tm2F3* for consistency.)
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Scheme 1. 
(a) Structure of L-a-amino acids and (b) examples of noncanonical amino acids (ncAAs).
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Scheme 2. 
The ncAA L-α−3-hydroxy-1-adamantyl-glycine is a building block of the diabetes drug 
saxagliptin.
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Scheme 3. 
Daptomycin, a cyclic peptide antibiotic, includes the ncAAs kynurenine (pink), ornithine 
(purple), (2S,3R)-methylglutamate (blue), as well as D-amino acids (green).
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Scheme 4. 
Selected representative methods for synthesizing ncAAs using chemical synthesis (blue) or 
biocatalysis (red).
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Scheme 5. 
Generalized mechanism of asymmetric amination by ammonia lyases.
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Scheme 6. 
Important species and features in the reaction of β-methylaspartate ammonia lyase (MAL).
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Scheme 7. 
MAL adds ammonia at the β-carbon of a carboxylate.
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Scheme 8. 
Generalized 4-methylidine-5-imidazolone (MIO)-dependent reaction for L-arylalanine 
synthesis by phenylalanine ammonia lyase (PAL).
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Scheme 9. 
The MIO-independent pathway of PAL from Anabaena variabilis (AvPAL).
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Scheme 10. 
The synthetic peptide cetrorelix contains three D-arylalanine ncAAs (blue).
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Scheme 11. 
(a) Chlorotryptophan is found in the antibiotic natural product rebeccamycin; (b) β-
methyltryptophan is found in natural products indolmycin and streptonigrin.
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Scheme 12. 
Reaction of TrpB with threonine, showing the loss of chirality in the β-methylamino-
acrylate (amino-crotylate) intermediate.
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Scheme 13. 
The 4-nitro groups disfavors nucleophilic attack (black arrows) by electron withdrawal (red 
arrows) and steric repulsion (blue dashed line).
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Scheme 14. 
Tumor-promoting indolactam V and the herbicide thaxtomin A are synthesized from 4-
nitrotryptophan.
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Table 1.
Yields and stereoselectivities for the amination of fumarate analogues by wild-type and engineered CtMAL 
variants are shown for four representative products under multiple conditions.23
L-aspartate threo-L-2-hexylaspartate threo-L-2-benzyloxyaspartate threo-L-2-benzylthioaspartate
Wild-type CtMAL yielda 100% 0% 0% 0%
CtMAL L384A yielda 99% 53% 60% 42%
CtMAL L384A yieldb ~100% ~85% ~90% ND
ee (de) >99% l ( - ) ND (>95% threo) >99% l (>95% threo) ND (20% threo)
a0.01 mol% catalyst, 10-fold molar excess ammonia.
b0.05 mol% catalyst, 5 M (167-fold molar excess) ammonia.
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